Gayathri R. Devi

Sort by:

X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor.

Katherine M Aird, Rami B. Ghanayem, Sharon Peplinski, H Kim Lyerly, Gayathri R. Devi
Molecular cancer therapeutics
2010

Inflammatory breast cancer (IBC) is a highly aggressive subtype of breast cancer that is often characterized by ErbB2 overexpression. ErbB2 targeting is clinically relevant using trastuzumab… (More)

Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression.

Katherine M Aird, Xiuyun Ding, +5 authors Gayathri R. Devi
Molecular cancer therapeutics
2008

Inflammatory breast cancer (IBC) patients show poor survival and a significant incidence of epidermal growth factor receptor-2 (ErbB2) overexpression. A distinct mechanism involving increased… (More)

XIAP as target for therapeutic apoptosis in prostate cancer.

Gayathri R. Devi
Drug news & perspectives
2004

Progression to androgen independence combined with chemotherapy resistance remains one of the primary obstacles to the improvement of quality of life and survival for patients with advanced prostate… (More)

ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells

Katherine M Aird, Jennifer L. Allensworth, Ines Batinić-Haberle, H Kim Lyerly, Mark W. Dewhirst, Gayathri R. Devi
Breast Cancer Research and Treatment
2011

Overexpression of epidermal growth factor receptors (ErbB) is frequently seen in inflammatory breast cancer (IBC). Treatment with ErbB1/2-targeting agents (lapatinib) mediates tumor apoptosis by… (More)

Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients

Michael Andew Morse, Abdul Rashid Chaudhry, +14 authors H. Kim Lyerly
Cancer Immunology, Immunotherapy
2013

First-generation, E1-deleted adenovirus subtype 5 (Ad5)-based vectors, although promising platforms for use as cancer vaccines, are impeded in activity by naturally occurring or induced Ad-specific… (More)

Cytotoxic effects of Mn(III) N-alkylpyridylporphyrins in the presence of cellular reductant, ascorbate.

Xiaodong Ye, Diane R Fels, +10 authors Ines Batinić-Haberle
Free radical research
2011

Due to the ability to easily accept and donate electrons Mn(III)N-alkylpyridylporphyrins (MnPs) can dismute O(2)(·-), reduce peroxynitrite, but also generate reactive species and behave as… (More)

X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells.

Adams Amantana, Carla A London, Patrick L. Iversen, Gayathri R. Devi
Molecular cancer therapeutics
2004

Androgen-insensitive prostate cancer cells are highly resistant to several chemotherapeutic drugs and are characterized by the appearance of apoptosis-resistant cells. In this study, we identified… (More)

Three-dimensional culture systems in cancer research: Focus on tumor spheroid model.

Sritama Nath, Gayathri R. Devi
Pharmacology & therapeutics
2016

Cancer cells propagated in three-dimensional (3D) culture systems exhibit physiologically relevant cell-cell and cell-matrix interactions, gene expression and signaling pathway profiles,… (More)

A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer

Michael Andew Morse, Donna Niedzwiecki, +17 authors H Kim Lyerly
Annals of surgery
2013

OBJECTIVE To determine whether 1 of 2 vaccines based on dendritic cells (DCs) and poxvectors encoding CEA (carcinoembryonic antigen) and MUC1 (PANVAC) would lengthen survival in patients with… (More)

An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer.

Michael Andew Morse, Amy C. Hobeika, +9 authors H Kim Lyerly
The Journal of clinical investigation
2010

Therapeutic anticancer vaccines are designed to boost patients' immune responses to tumors. One approach is to use a viral vector to deliver antigen to in situ DCs, which then activate tumor-specific… (More)

Filter Results:

Publication Year

Publication Type

Co-author

Journals and Conferences